Helius Medical Technologies Faces Volatility Amid Key Updates

Introduction

HELIUS MEDICAL TECHNOLOGIES INC (NASDAQ: HSDT) develops non-implantable neuromodulation devices aimed at addressing neurologic deficits. Its primary product, the Portable Neuromodulation Stimulator (PoNS®), delivers electrical stimulation to the tongue surface during supervised therapeutic exercise. As of June 27, 2025, HSDT shares closed at $0.2361, representing a 30.54% decline for the day, with a trading volume of 1,428,867 shares on the Nasdaq Capital Market.

Corporate Structure and Workforce

Headquartered in Newtown, Pennsylvania, Helius Medical Technologies employs between 11 and 50 staff according to LinkedIn data. The company’s leadership includes its Chief Executive Officer, President, and Chief Medical Officer, supported by teams in manufacturing, quality, supply chain, and commercial access. Career opportunities at Helius focus on research, development, and implementation of neurotechnology for patients.

Neuromodulation by Maxim Potkin ❄

Recent Developments and News

• January 22, 2025: Helius reported results from the PoNS Therapeutic Experience Program (PoNSTEP) study in individuals with multiple sclerosis. Among 38 participants, the mean improvement on the Dynamic Gait Index was 5.00 points (p<0.001) at Week 14, with benefits observed six months post-treatment.
• April 30, 2025: Helius announced a 1-for-15 reverse stock split, which took effect on May 2, 2025, reducing outstanding shares from approximately 7.9 million to 0.5 million, with the CUSIP changing to 42328V 884.
• June 6, 2025: Helius completed a public offering, raising $9.1 million through the sale of 2,768,600 shares of Class A common stock and accompanying warrants at a price of $3.27 per share.
• June 20–27, 2025: The company filed three Form 8-K reports addressing a management change (Item 5.02), operational updates (Items 8.01 and 9.01), and amendments affecting security holder rights (Items 3.03, 5.03, and 9.01).

Financial and Strategic Analysis

Helius Medical Technologies operates at an early commercial stage. Key trailing-twelve-month metrics from Yahoo Finance as of June 13, 2025, include:

• Market Capitalization: $1.606 million
• Revenue (TTM): $434,000
• Net Loss (TTM): $13.06 million
• Diluted EPS (TTM): –26.40
• Price/Sales: 0.34 x; Price/Book: 0.21 x
• Total Cash (most recent quarter): $1.11 million; Levered Free Cash Flow: –$6.17 million

The company has sought regulatory clearances and market authorizations in Canada (for balance deficits due to mmTBI, gait deficits in multiple sclerosis, and stroke), the United States (for gait deficits in MS), and Australia (for balance and gait as adjunct therapy). The reverse stock split and equity raise were conducted to meet Nasdaq listing requirements and enhance liquidity for continued PoNS therapy training and clinical research.

Market Position and Industry Context

Operating in the medical device and neurotechnology sector, Helius addresses functional neurological deficits through non-invasive neuromodulation. The PoNS system competes with other rehabilitation technologies—such as robotics, exoskeletons, and electrical stimulation—by focusing on portability and patient-driven therapy. Progress in third-party reimbursement, including out-of-network authorization from CignaHealth, indicates increasing acceptance of neuroplasticity-based treatments. Ongoing clinical publications and strategic partnerships will influence Helius’s position in gait and balance rehabilitation.

tl;dr

On June 27, 2025, HSDT closed at $0.2361 (–30.54%) amid heightened volatility following:

• January 22: PoNSTEP study indicated durable gait improvements in MS patients
• April 30/May 2: 1-for-15 reverse stock split executed to comply with Nasdaq listing standards
• June 6: $9.1 million public offering concluded at $3.27 per share
  Upcoming events include earnings guidance (Aug 11–15, 2025) and further reimbursement decisions that may impact liquidity and market adoption of PoNS® therapy.